Based on the available evidence, IL-1 blockers are mostly reserved for patients with the auto-inflammatory pericarditis phenotype (namely with striking CRP elevation, fever, and serositis), depicting recurrences despite an optimal treatment of pericarditis with first- or second-line agents. Here, IL1B is linked to pericarditis.